The stock of Lyell Immunopharma Inc (LYEL) has seen a 6.11% increase in the past week, with a -24.33% drop in the past month, and a -21.23% decrease in the past quarter. The volatility ratio for the week is 11.23%, and the volatility levels for the past 30 days are at 12.40% for LYEL. The simple moving average for the past 20 days is -9.71% for LYEL’s stock, with a -55.64% simple moving average for the past 200 days.
Is It Worth Investing in Lyell Immunopharma Inc (NASDAQ: LYEL) Right Now?
Moreover, the 36-month beta value for LYEL is -0.17. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for LYEL is 124.86M and currently, short sellers hold a 4.57% of that float. On April 17, 2025, LYEL’s average trading volume was 997.90K shares.
LYEL) stock’s latest price update
Lyell Immunopharma Inc (NASDAQ: LYEL)’s stock price has plunge by 0.28relation to previous closing price of 0.44. Nevertheless, the company has seen a 6.11% surge in its stock price over the last five trading sessions. globenewswire.com reported 2025-04-15 that SOUTH SAN FRANCISCO, Calif., April 15, 2025 (GLOBE NEWSWIRE) — Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to LYL314 (formerly IMPT-314) for the treatment of adult patients with relapsed and/or refractory large B-cell lymphoma after two or more prior lines of therapy. LYL314 is a next-generation dual-targeting CD19/CD20 CAR T-cell product candidate designed to increase complete response rates and prolong the duration of response as compared to the approved CD19‑targeted CAR T-cell therapies for the treatment of aggressive large B-cell lymphoma (LBCL).
Analysts’ Opinion of LYEL
Many brokerage firms have already submitted their reports for LYEL stocks, with BofA Securities repeating the rating for LYEL by listing it as a “Underperform.” The predicted price for LYEL in the upcoming period, according to BofA Securities is $1 based on the research report published on October 30, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see LYEL reach a price target of $1, previously predicting the price at $6. The rating they have provided for LYEL stocks is “Neutral” according to the report published on June 27th, 2024.
JP Morgan gave a rating of “Neutral” to LYEL, setting the target price at $5 in the report published on August 28th of the previous year.
LYEL Trading at -23.14% from the 50-Day Moving Average
After a stumble in the market that brought LYEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.69% of loss for the given period.
Volatility was left at 12.40%, however, over the last 30 days, the volatility rate increased by 11.23%, as shares sank -17.42% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.97% lower at present.
During the last 5 trading sessions, LYEL rose by +6.15%, which changed the moving average for the period of 200-days by -72.13% in comparison to the 20-day moving average, which settled at $0.4876. In addition, Lyell Immunopharma Inc saw -31.21% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LYEL starting from BRAWLEY OTIS W, who purchase 35,640 shares at the price of $0.56 back on Mar 31 ’25. After this action, BRAWLEY OTIS W now owns 35,640 shares of Lyell Immunopharma Inc, valued at $19,958 using the latest closing price.
Ramachandra Sumant, the Director of Lyell Immunopharma Inc, purchase 200,000 shares at $0.58 during a trade that took place back on Mar 21 ’25, which means that Ramachandra Sumant is holding 200,000 shares at $115,220 based on the most recent closing price.
Stock Fundamentals for LYEL
Current profitability levels for the company are sitting at:
- -5919.49 for the present operating margin
- -161.7 for the gross margin
The net margin for Lyell Immunopharma Inc stands at -5622.85. The total capital return value is set at -0.83. Equity return is now at value -66.10, with -55.28 for asset returns.
Based on Lyell Immunopharma Inc (LYEL), the company’s capital structure generated 0.13 points at debt to capital in total, while cash flow to debt ratio is standing at -2.75.
Currently, EBITDA for the company is -3.31 million with net debt to EBITDA at 0.23. When we switch over and look at the enterprise to sales, we see a ratio of 1351.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.06.
Conclusion
To wrap up, the performance of Lyell Immunopharma Inc (LYEL) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
